Related Experiment Video

Updated: Apr 11, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

4.0K

Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

Armin Rashidi1, Amanda F Cashen1

  • 11Division of Oncology, Washington University School of Medicine, 660 S Euclid Avenue, Campus Box 8007, St Louis, MO 63110, USA.

Future Oncology (London, England)
|June 5, 2015
PubMed

Insights

Belinostat is an effective histone deacetylase (HDAC) inhibitor for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). This well-tolerated drug shows promise in clinical trials for various cancers, often in combination therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Peripheral T-cell lymphoma (PTCL) has a poor prognosis, especially in relapsed/refractory cases.
  • Current treatments for relapsed/refractory PTCL offer limited efficacy.
  • Histone deacetylase (HDAC) inhibitors represent a promising therapeutic class for PTCL.

Purpose of the Study:

  • To review the pharmacology of belinostat.
  • To summarize the clinical activity of belinostat in relapsed/refractory PTCL.
  • To highlight ongoing investigations of belinostat in various cancers.

Main Methods:

  • Review of published literature on belinostat's pharmacology and clinical trials.
  • Analysis of clinical trial data regarding belinostat's efficacy and tolerability.
  • Synthesis of information on belinostat's mechanism of action as an HDAC inhibitor.

Main Results:

  • Belinostat is a well-tolerated HDAC inhibitor.
  • Belinostat demonstrates clinical activity in heavily pretreated PTCL patients.
  • Belinostat is approved for treating relapsed/refractory T-cell lymphoma.

Conclusions:

  • Belinostat offers a viable treatment option for relapsed/refractory PTCL.
  • Belinostat's favorable tolerability profile supports its clinical use.
  • Ongoing trials are exploring belinostat's potential in combination therapies and other malignancies.
Keywords:
T-cell lymphomabelinostathistone deacetylase inhibitor

More Related Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

16.0K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K